Apeximmune Therapeutics has successfully closed its Series A funding round, raising $21.3 million led by PharmaEssentia Corporation. The funds will advance the development of their first-in-class immunotherapy, AI-306.
Amount Raised
$21.3 Million
Round Type
Series A
BurlingameBiotechnologyHealth CareTherapeuticsInvestors
Description
Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, announced the successful close of its Series A financing round, raising $21.3 million. The funding was led by PharmaEssentia Corporation, with notable participation from several investors, including DCI Partners and Taya Venture Capital. The proceeds will focus on accelerating the development of AI-306, their lead candidate targeting gastrointestinal cancers. CEO Dr
Quick answer
Apeximmune Therapeutics raised $21.3 Million in a Series A round, dated April 1, 2025. Investors: Judy Swanson, Hercules BioVenture LP, PharmaEssentia Corporation, DCI Partners, Taya Venture Capital, Kdi Marketing, Huahai Us and Ttm 2025 Llc. Apeximmune Therapeutics is based in Burlingame, California, United States.
- How much did Apeximmune Therapeutics raise?
- Apeximmune Therapeutics raised $21.3 Million in a Series A round on April 1, 2025.
- Who invested in Apeximmune Therapeutics?
- Judy Swanson, Hercules BioVenture LP, PharmaEssentia Corporation, DCI Partners, Taya Venture Capital, Kdi Marketing, Huahai Us and Ttm 2025 Llc are named as investors in this round.
- What does Apeximmune Therapeutics do?
- Apeximmune Therapeutics is a biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune diseases.
- Where is Apeximmune Therapeutics based and how big is it?
- Apeximmune Therapeutics is based in Burlingame, California, United States. Fundz records about 7 employees.
- Who are the decision-makers at Apeximmune Therapeutics?
- Fundz holds 1 contact at Apeximmune Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Apeximmune Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Cellestial Health raised an undisclosed amount (Pre-Seed) on May 9, 2025.
- ImmuneWalk Therapeutics raised $7M (Seed) on May 8, 2025.
- Avammune Therapeutics raised $12M (Series A) on May 7, 2025.
- PAQ Therapeutics raised $39M (Series B) on May 7, 2025.
- Paradigm Therapeutics raised $13M (Funding Round) on May 6, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.8M on May 2, 2025.
Who to call at Apeximmune Therapeutics, and when
A new round usually means Apeximmune Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Apeximmune Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Apeximmune Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Apeximmune Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Apeximmune Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansApeximmune Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.